REFERENCES
1. Duley L. The Global Impact of Pre-eclampsia and Eclampsia. Semin
Perinatol. 2009;33(3):130–7.
2. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates
of preeclampsia, eclampsia, and gestational hypertension, United States,
1987-2004. Am J Hypertens. 2008;21:521–6.
3. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R.
Pre-eclampsia. Lancet. 2010;376(9741):631–44.
4. Von Dadelszen P, Magee LA, Roberts JM. Subclassification of
Preeclampsia. Hypertens Pregnancy. 2003;22(2):143–8.
5. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric
placental villous and vascular abnormalities in early- and late-onset
pre-eclampsia with and without fetal growth restriction. BJOG An Int J
Obstet Gynaecol. 2006;113(5):580–9.
6. Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy
Hypertens. 2012;2(2):72–83.
7. Lisonkova S, Joseph KS. Incidence of preeclampsia: Risk factors and
outcomes associated with early-versus late-onset disease. Am J Obstet
Gynecol. 2013;209(6):544.e1-544.e12.
8. Weitzner O, Yagur Y, Weissbach T, Man El G, Biron-Shental T.
Preeclampsia: risk factors and neonatal outcomes associated with early-
versus late-onset diseases. J Matern Neonatal Med. 2018;6:1–5.
9. Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or
expectant management for patients with severe preeclampsia between 28-34
weeks’ gestation: a randomized controlled trial. Obstet Gynecol.
1990;76:1070–5.
10. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus
expectant management of severe preeclampsia at 28 to 32 weeks’
gestation: a randomized controlled trial. Vol. 171, American journal of
obstetrics and gynecology. 1994.
11. von Dadelszen P, Menzies JM, Payne B, Magee LA. Predicting Adverse
Outcomes in Women with Severe Pre-eclampsia. Semin Perinatol.
2009;33(3):152–7.
12. Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von
Dadelszen P, et al. Prediction of complications in early-onset
pre-eclampsia (PREP): development and external multinational validation
of prognostic models. BMC Med. 2017;15(1):1–11.
13. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M,
et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected
Preeclampsia. N Engl J Med. 2016;374(1):13–22.
14. Chappell L, Duckworth S, Seed P, Griffin M, Myers J, Mackillop L, et
al. Diagnostic Accuracy of Placental Growth Factor in Women With
Suspected Preeclampsia. Circulation. 2013;128(19):2121–31.
15. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M,
et al. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor
Ratio and Time to Delivery in Women with Suspected Preeclampsia. Obstet
Gynecol. 2016;128(2):261–9.
16. Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W, et al.
The importance of repeated measurements of the sFlt-1/PlGF ratio for the
prediction of preeclampsia and intrauterine growth restriction. J
Perinat Med. 2014;42(1):61–8.
17. Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors
in early-vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med.
2013;41(5):511–6.
18. Baltajian K, Bajracharya S, Salahuddin S, Berg AH, Geahchan C,
Wenger JB, et al. Sequential plasma angiogenic factors levels in women
with suspected preeclampsia. Am J Obstet Gynecol. 2016
Jul;215(1):89.e1-89.e10.
19. Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal
Morbidity Associated With Early-Onset and Late-Onset Preeclampsia.
Obstet Gynecol. 2014 Oct;124(4):771–81.
20. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et
al. The classification, diagnosis and management of the hypertensive
disorders of pregnancy: A revised statement from the ISSHP. Pregnancy
Hypertens. 2014;4(2):97–104.
21. Robinson H, Fleming J. A critical evaluation of sonar “crown-rump
length” measurements. Br J Obs Gynaecol. 1975;82:702–10.
22. American College of Obstetricians and Gynecologists; Task Force on
Hypertension in pregnancy. Hypertension in Pregnancy. Obstet Gynecol.
2013;122(5):1122–31.
23. Thangaratinam S, Allotey J, Marlin N, Mol BW, Von Dadelszen P,
Ganzevoort W, et al. Development and validation of Prediction models for
Risks of complications in Early-onset Pre-eclampsia (PREP): a
prospective cohort study. Heal Technol Assess. 2017;21(18).
24. Teasdale G, Jennet B. Assessment of coma and impaired consciousness.
A practical scale. Lancet. 1974;2(7872):81–4.
25. Kamath PS, Kim WR. The Model for End-stage Liver Disease (MELD).
Hepatology. 2007;45(3):797–805.
26. Murali A, Devarbhavi H, Venkatachala P, Singh R, Sheth K. Factors
that predict 1-month mortality in patients with pregnancy-specific liver
disease. Clin Gastroenterol Hepatol. 2014;12(1):109–13.
27. Kellum JA. Acute kidney injury. Crit Care Med. 2008;36(4
Suppl):S141-5.
28. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA,
Baker PN, et al. Consensus definition of fetal growth restriction: a
Delphi procedure. Ultrasound Obs Gynecol. 2016/02/26. 2016;48(3):333–9.
29. Macones GA, Hankins GD V, Spong CY, Hauth J, Moore T. The 2008
National Institute of Child Health and Human Development workshop report
on electronic fetal monitoring: update on definitions, interpretation,
and research guidelines. Obstet Gynecol. 2008 Sep;112(3):661–6.
30. Figueras F, Gratacos E. An integrated approach to fetal growth
restriction. Best Pract Res Clin Obstet Gynaecol. 2017;38:48–58.
31. Meler E, Figueras F, Bennasar M, Gomez O, Crispi F, Gratacos E. The
prognostic role of uterine artery Doppler investigation in patients with
severe early-onset preeclampsia. Am J Obstet Gynecol. 2010
Jun;202(6):559.e1-4.
32. Schoenfeld DA, Richter JR. Nomograms for calculating the number of
patients needed for a clinical trial with survival as an endpoint.
Biometrics. 1982 Mar;38(1):163–70.
33. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto
E, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic
factors are of prognostic value in patients presenting to the
obstetrical triage area with the suspicion of preeclampsia. J Matern
Fetal Neonatal Med. 2011 Oct;24(10):1187–207.
34. Staff AC, Benton SJ, Von Dadelszen P, Roberts JM, Taylor RN, Powers
RW, et al. Redefining preeclampsia using placenta-derived biomarkers.
Hypertension. 2013;61(5):932–42.
35. Levine R, Maynard S, Qian C, Lim K, England L, Yu K, et al.
Circulating Angiogenic Factors and the Risk of Preeclampsia. N Engl J
Med. 2004;350(7):672–83.
36. Saleh L, van den Meiracker AH, Geensen R, Kaya A, Roeters van Lennep
JE, Duvekot JJ, et al. Soluble fms-like tyrosine kinase-1 and placental
growth factor kinetics during and after pregnancy in women with
suspected or confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2018
Jun;51(6):751–7.
37. Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennström M,
et al. Soluble fms-like tyrosine kinase-1 to placental growth factor
ratio: ruling out pre-eclampsia for up to 4 weeks and value of
retesting. Ultrasound Obstet Gynecol. 2019;53(3):367–75.
38. Huppertz B. An updated view on the origin and use of angiogenic
biomarkers for preeclampsia. Expert Rev Mol Diagn. 2018;18(12):1053–61.
39. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor
and its receptor, vascular endothelial growth factor receptor-1: novel
targets for stimulation of ischemic tissue revascularization and
inhibition of angiogenic and inflammatory disorders. J Thromb Haemost.
2003 Jul;1(7):1356–70.
40. Maynard SE, Min J, Merchan J, Lim K-H, Li J, Mondal S, et al. Excess
Placental Soluble fms-like Hypertension , and Proteinuria in. J Clin
Invest. 2003;111(5):649–58.
41. Gillon TER, Pels A, Von Dadelszen P, MacDonnell K, Magee LA.
Hypertensive Disorders of Pregnancy: A Systematic Review of
International Clinical Practice Guidelines. PLoS One.
2014;9(12):e113715.
42. Magee LA, Yong PJ, Espinosa V, Côté AM, Chen I von DP. Expectant
Management of Severe Preeclampsia Remote from Term: A Structured
Systematic Review. Hypertens Pregnancy. 2009;28(3):312–47.
43. Magee LA, Helewa M, Rey E, Cardew S, Côté AM, Douglas MJ, et al.
Diagnosis, Evaluation, and Management of the Hypertensive Disorders of
Pregnancy. J Obstet Gynaecol Canada. 2008;30(3):S1–2.
44. Von Dadelszen P, Payne B, Li J, Ansermino JM, Pipkin FB, Côté AM, et
al. Prediction of adverse maternal outcomes in pre-eclampsia:
Development and validation of the fullPIERS model. Lancet.
2011;377(9761):219–27.